Santé log15h
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis
Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.
manilatimes23h
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
Medscape23h
Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI
For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
PMLiVE3d
J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial
Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...
Pharmabiz5d
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...
Hosted on MSN6d
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis Patients
Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...